The company’s Eysuvis looks set to be approved for dry eye disease, but meeting expectations in this tough market will not be easy.
On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.
Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
Others in the FDA queue include Bausch’s psoriasis therapy Duobrii and Motif Bio’s antibiotic Iclaprim.
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
After years in the wilderness, the UK cell therapy specialist Reneuron could be about to seal a deal with a big US player.